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a  b  s  t  r  a  c  t
Osteoporosis is a well-established extra-articular feature of rheumatoid arthritis (RA). Sys-
temic inﬂammation seems to play a crucial role in causing an alteration of multiple
homeostatic systems implied in bone health, such as the RANK/RANKL/Osteoprotegerin and
Wnt/  catenin pathways; several other causal factors have been called into question, includ-
ing the chronic use of corticosteroids. Since vitamin D exerts important immune-regulatory
roles, it has been claimed that derangement of the vitamin D/parathyroid hormone (PTH)
system, a well-known determinant of bone health, may play a pathogenic role in autoim-
munity;  animal models and clinical data support this hypothesis. Furthermore, RA patients
seem to be relatively refractory to vitamin D-induced PTH suppression. Therefore, the link
between RA and osteoporosis might in part be due to alterations in the vitamin D/PTH sys-
tem.  A better understanding of the pathophysiology of this system may be crucial to prevent
and cure osteoporosis in patients with inﬂammatory/autoimmune diseases. A major clin-
ical  correlate of the strict cooperation and interdependence between vitamin D and PTH
is  that correction of the vitamin D deﬁciency, at least in autoimmune diseases, should be
targeted to PTH suppression.
© 2014 Elsevier Editora Ltda. All rights reserved.
Osteoporose  na  artrite  reumatoide:  papel  do  sistema  vitamina
D/hormônio  paratireóideo
r  e  s  u  m  oPalavras chave: A osteoporose é uma característica extra-articular bem estabelecida da artrite reuma-




em  múltiplos sistemas homeostáticos implicados na saúde óssea, como as vias
RANK/RANKL/osteoprotegerina e Wnt/ catenina; vários outros fatores causais têm sido
implicados, como o uso crônico de corticosteroides. Como a vitamina D exerce func¸ões
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imunorreguladoras importantes, tem-se aﬁrmado que o desarranjo do sistema vitamina
D/hormônio paratireóideo (HPT), um determinante bem conhecido da saúde óssea, pode
desempenhar um papel patogênico na autoimunidade; estudos com animais e dados clíni-
cos  apoiam essa hipótese. Além disso, os pacientes com AR parecem ser relativamente
refratários à supressão de HPT induzida pela vitamina D. Portanto, a ligac¸ão entre a AR e
a  osteoporose pode ser em parte causada por alterac¸ões no sistema vitamina D/HPT. Uma
melhor compreensão da ﬁsiopatologia desse sistema pode ser crucial para prevenir e curar
a  osteoporose em pacientes com doenc¸as inﬂamatórias/autoimunes. A maior evidência da
correlac¸ão  clínica de cooperac¸ão e interdependência entre a vitamina D e o HPT é que
a  correc¸ão da deﬁciência de vitamina D, pelo menos nas doenc¸as autoimunes, deve ser
orientada para a supressão do HPT.






































steoporosis is a frequent complication of autoimmune
nﬂammatory diseases, such as rheumatoid arthritis (RA),
nkylosing spondylitis (AS), systemic lupus erythematosus
SLE) and multiple sclerosis (MS).1 The reasons why osteoporo-
is occurs in these diseases are multiple and not completely
nderstood. The failure of several bone regulation systems has
een claimed to be responsible for this complication of sys-
emic inﬂammatory diseases even though this issue remain
artially unresolved.
The vitamin D/PTH system is a well known determinant
f bone health in the general population. Recently, a failure in
itamin D metabolism has been described in patients affected
y inﬂammatory rheumatic diseases,2 even though its rela-
ionship with the pathogenesis of autoimmune diseases and
he consequences on bone health remain not completely
nderstood. In this paper we  will review the role of the vitamin
/PTH system in the pathogenesis of osteoporosis in autoim-
une diseases and, in particular, in RA.
To perform the present review, we  interrogated PubMed
accessed on-line on July 1st, 2013), limiting our search to
apers published in English until June 30th, 2013, and using
he following string: “(vitamin D PTH system) OR (vitamin
 rheumatoid arthritis) OR (rheumatoid arthritis secondary
yperparathyroidism) OR (rheumatoid arthritis hypovita-
inosis D)” yielded 856 articles. Eight-hundred papers were
xcluded for the following reasons: (a) dealt with topics non-
elevant for the present review, (b) letters, case reports, (c)
mall sample size, (d) unobtainable full text articles, or a com-
ination of the above reasons. We  reviewed all the remaining
apers, plus additional relevant articles identiﬁed from the
eferences of selected articles or through personal knowledge
f the authors.
steoporosis  and  autoimmune  inﬂammatory  diseases
steoporosis is a clinical condition characterized by a high
isk of vertebral and non-vertebral fractures, due to the reduc-
ion of Bone Mineral Density (BMD). It also represents a well
stablished extra-articular feature of RA.3
Patients affected by RA have been reported to be at higher
isk of vertebral and non vertebral fractures.4,5 With respectto the reference population values, female RA patients dis-
play lower bone mineral density (BMD) values at the hip
and the spine; the risk of osteoporosis seems to be higher
among patients who are older, postmenopausal, positive for
Rheumatoid Factor, treated with corticosteroids, have longer
disease duration and higher burden of disability.6 Recently,7
in a perspective cohort of 102 RA patients who  completed a
5-years follow-up, an annual incidence of vertebral fractures
of 3.7/100 patients/year has been reported, higher than in the
general population according to other prospective studies.8,9
The annual incidence of non vertebral fractures was also
increased. These data have been conﬁrmed by other studies10
in which the risk of all fractures in RA patients was 1.5-fold
higher than healthy controls.
However, the increased risk of osteoporosis is not limited
to RA patients but has been also reported for other autoim-
mune diseases such as MS, AS, and SLE.1 The reasons why
patients affected by autoimmune inﬂammatory diseases are
prone to develop osteoporosis are complex. A central role
seems to be played by systemic inﬂammation. Receptor Acti-
vator of Nuclear Factor Kappa B (RANK) is a nuclear receptor
expressed by osteoclast precursors and mature osteoclasts,
which mediates osteoclastogenesis after binding to its ligand,
RANKL.11 In patients with RA the overexpression of several
inﬂammatory cytokines (TNF-,  interleukin (IL)-1, IL-6 and IL-
17) favors the activation, differentiation and proliferation of
osteoclasts induced by RANKL.12,13 This system is further reg-
ulated by osteoprotegerin (OPG), a decoy receptor expressed
by osteoblasts which competes with RANK for the binding to
RANKL; so, OPG is an inhibitor of osteoclast activation in vitro
and in vivo.14
Furthermore TNF can also induce osteocytes to synthetize
sclerostin and Dkk-1,15 two inhibitors of the Wnt/ catenin
pathway, a crucial system for osteoblastic differentiation.16,17
In a recent study on RA patients, a osteoprotegerin/RANKL
ratio 5 times lower than that observed in healthy controls
has been reported, with an inverse correlation between circu-
lating osteoprotegerin and the disease activity score DAS28,
and a positive correlation between RANKL and C-reactive pro-
tein. Furthermore, Dkk-1 and sclerostin levels were higher in
RA patients than in healthy controls. After two  months of
treatment with tocilizumab (a humanized anti-interleukin-6
receptor antibody), the osteoprotegerin/RANKL ratio increased
proportionally to clinical improvement and suppression of
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Fig. 1 – Vitamin D metabolism. Cholecalciferol, both deriving from dietary intake and from endogenous synthesis, circulates
in the blood bound to a vitamin D binding protein. Then, it is hydroxylated to 25(OH) cholecalciferol by a liver enzyme and
further hydroxylated to 1,25(OH)2D by CYP27B1, expressed by kidney, but also by several other tissues. The inactivation is
mediated by 24-hydroxylation.inﬂammation; furthermore, sclerostin increased while Dkk-1
decreased with respect to baseline.18
Similar data have also been obtained with other biologics;
in fact, the improvement of inﬂammation control with inﬂix-
imab  has been associated with a reduction in bone loss.19
One other major factor in the pathogenesis of osteoporosis
in rheumatic diseases is the long term use of corticosteroids.
It is known that glucocorticoids can induce osteoporosis
through different mechanisms20: in fact, the use of glucocor-
ticoids reduces the number and the function of osteoblasts21
and impairs their differentiation and maturation22 through
interference with Wnt/-catenin signaling.23 In this context,
the apoptosis of osteoblasts and osteocytes is enhanced,24 the
expression of RANK-L increased and that of OPG decreased25
favoring the activation of osteoclasts. In the clinical setting
glucocorticoid treatment is an independent risk factor for
bone loss26; in a meta-analysis on 2891 steroid users gluco-
corticoid treatment has been linked dose dependently to bone
loss and risk fractures, in particular in the ﬁrst months of
treatment. The risk decreases after stopping therapy. However,
doses as low as 5 mg/day have been reported to increase the
risk of fractures of approximately 20%; interestingly, higher
initial doses are stronger related to the risk of bone loss
than higher cumulative doses.27 According to ACR guidelines,
any patient starting a long term (>3 months) steroid reg-
imen should receive calcium and vitamin D; furthermore,
bisphosphonates should be started according to the assessed
osteoporosis risk.28
Vitamin  D  metabolismVitamin D is a secosteroid hormone that in the body is derived
both from dietary intake and endogenous synthesis. Several
foods are dietary sources of Vitamin D, either as Vitamin D2(ergocalciferol) or Vitamin D3 (cholecalciferol), including cod
oil, ﬁsh and fortiﬁed milk. However, the greater part of Vita-
min  D required for metabolism originates from endogenous
synthesis. The metabolic pathways start from the activa-
tion of a precursor (7-dehydrocholesterol) in the skin which
is photolysed into cholecalciferol following sun exposure;
cholecalciferol is then hydroxylated to 25-hydroxyvitamin D
(25(OH)D) by different isoforms of a 25-hydroxylase (CYP2C11,
CYP2J3, CYP2R1, CYP3A2, CYP27A1) in the liver. 25(OH)D is the
circulating form of the vitamin, bound to Vitamin D binding
protein (DBP). 25(OH)D can also be stored in fat tissue, and is
the intermediate metabolite usually measured to deﬁne the
vitamin D status, because it is more  stable and has a longer
life than the active form.29
1,25-Dihydroxyvitamin D (1,25(OH)2D, also called calcitriol)
represents the active form, and it is the result of a further
hydroxylation step mediated by 1--hydroxylase (CYP27B1)
expressed in kidney (Fig. 1). This is the most important
check-point of Vitamin D metabolism and CYP27B1 activity
is strictly controlled: in particular PTH induces its activity,30
while high serum calcium concentration and 1,25(OH)2D
down regulate its expression.31 While the expression of 25-
hydroxylase seems to be restricted to the liver, CYP27B1 is
expressed by many  other tissues, including placenta, endothe-
lium, prostate, monocytes and macrophages, skin, colon and
brain.32
1,25(OH)2D acts on its target cells through a nuclear
receptor (vitamin D receptor – VDR). The binding between
1,25(OH)2D and VDR induces the heterodimerization with RXR
(retinoid X receptor); the VDR/RXR complex modulates both
positively and negatively the expression of many  downstream
genes, linking speciﬁc DNA regions (VDRE – vitamin D respon-
sive elements). Corepressors and coactivators can contribute
to VDR/RXR complex activity (Fig. 2).33









Fig. 2 – Mechanism of action of vitamin D. The active form
of vitamin D reaches the cytoplasm, where it binds to VDR
(vitamin D receptor), inducing nuclear translocation and
further association to RXR (retinoid X receptor), thereby
creating a transcriptional complex together to RNA
polymerase (RNApol) and a co-activator (CoA) able to induce
or repress genes transcription. This complex recognizes






























dendritic cells (DC) maturation down-regulating the expres-
sion of molecules of the class II major histocompatibilityitamin  D/PTH  system  and  bone  health
he classic and best deﬁned function of vitamin D is the regu-
ation of calcium/phosphorus metabolism, which is essential
o grant bone health. In particular 1,25(OH)2D induces gut
bsorption of calcium and phosphorus34; furthermore it
cts on kidney tubules determining an increase in calcium
eabsorption.35 The global result is an increase in plasma cal-
ium and phosphorus concentration.
1,25(OH)2D has various effects on bone cells: in particular,
t increases the expression of osteopontin36 and osteocalcin37
n osteoblasts, increases the RANKL expression on the plasma
embrane of osteoblasts and inhibits the synthesis of
PG. Thereby, vitamin D increases the number of RANKL
olecules able to bind to RANK, allowing a physiological bone
urnover.38
It is well known that vitamin D actions on bone are
trictly linked to PTH activity, because vitamin D needs PTH
o play its role on bone, but also because vitamin D down
egulates PTH synthesis both indirectly (increasing calcium
oncentration) and directly (activating a VDRE in the pro-
oter of the PTH gene). Vitamin D also inhibits parathyroid
ells proliferation39 and modulates the sensitivity to cal-
ium, increasing the transcription of CasR (Calcium Sensing
eceptor).40
These molecular pathways have important clinical impli-
ations. First, even though in the last decade other bone health
eterminants have been used to deﬁne vitamin D status, the
eﬁnition of a normal plasma vitamin D concentration is
ainly based on the identiﬁcation of a 25(OH)D plasma con-entration able to suppress PTH. This threshold of normality
as been set by some at 30 ng/mL (75 nmoL/L).41 5;5 5(3):256–263 259
Therefore, patients affected by severe vitamin D deﬁciency
can suffer a secondary hyperparathyroidism responsible of an
inadequate bone mineralization leading to rickets or osteo-
malacia; in the modern era these conditions have become
rare, although hypovitaminosis D is extremely common in
the general population. The impact of hypovitaminosis D
on bone outcomes is still debated, in particular with regard
to the relationship between lower vitamin D levels and the
risk of falls and fractures. In a systematic review vitamin D
concentration correlated positively with BMD  and inversely
with the risk of falls,42 while a correlation with an increased
risk of fractures lacked consistence. These data conﬁrmed
the direct relationship between vitamin D concentrations
and BMD  observed in a large population of postmenopausal
women,43 as well as in the community-dwelling men  and
women aged at least 20 years who participated to the US
NHANES III survey.44 However, recently, hypovitaminosis D
has been also associated to an increased risk of vertebral
fractures.45
Even though the deﬁnition of normal 25(OH)D plasma con-
centration is still debated, a classiﬁcation of vitamin D status
on which many  would agree is: deﬁciency 25(OH)D <20 ng/mL
(<50 nmoL/L), insufﬁciency 20–30 ng/mL (50–75 nmoL/L), nor-
mality >30 ng/mL (>75 nmoL/L).46
Vitamin D supplementation seems to be linked to favor-
able clinical outcomes. In particular the resolution of vitamin
D deﬁciency is associated with a recovery in bone mineral
density47; furthermore vitamin D supplementation reduces
the risk of falls and fractures according to the results of a
meta-analysis.48,49
It was suggested that a 25(OH)D plasma concentration of
at least 60 nmoL/L is necessary for prevention of falls and
fractures.50 However the preferable regimen of vitamin D
supplementation has not been established yet and several
different schemes have been suggested.51–53 Recently46 pub-
lished guidelines suggested the use of high doses (2000 IU/day
or 50,000 IU once weekly for 6 weeks) ergocalciferol or chole-
calciferol in the correction of hypovitaminosis D, followed by
a maintenance daily dose of 400–1000 IU/day.
However, a randomized clinical trial in 2010 surpris-
ingly reported an increased risk of falls and fractures in
patients treated with one single annual dose of 500,000 IU
cholecalciferol.54 Although these data await conﬁrmation in
other studies, this observation question the safety of admin-
istering single high dose cholecalciferol.
Vitamin  D  in  autoimmune  diseases
In the past few years, several reports pointed out a putative
role for the active metabolite 1-25(OH)2D in immune system
regulation. This hypothesis is based on the observations that
1-25(OH)2D has immuno-modulatory effects on cells of the
innate immunity. In fact, in vitro, it induces the differentia-
tion of monocytes with inhibition of inﬂammatory cytokines
production (TNF-,  IL-6, IL-1). Moreover, 1-25(OH)2D decreasescomplex, and of CD40, CD80, CD83 and CD86, and favoring the
activation of CD4 T lymphocytes with a Th2 phenotype.55–57
 o l . 2260  r e v b r a s r e u m a t
The importance of vitamin D metabolites in immune regu-
lation is conﬁrmed by recent data showing that macrophages
and monocyte-derived DCs express the enzyme CYP27B1.
In this way, 1-25(OH)2D is generated locally and binds
to VDR in immune cells, thereby exerting concentration-
dependent anti-inﬂammatory autocrine and paracrine effects
in lymphoid microenvironments.32 In addition, some epi-
demiological studies have correlated hypovitaminosis D to
the development of autoimmune diseases, such as multi-
ple sclerosis, type I diabetes, systemic sclerosis, SLE and
RA.58 In fact, a lower dietary intake of vitamin D has been
linked to a higher risk of RA development in a meta-
analysis of several studies59; furthermore, plasma 25(OH)D
concentration has been reported to be lower in RA patients
when compared to healthy controls,60 although these results
were not conﬁrmed in other studies.61 Plasma 25(OH)D con-
centration has also been inversely correlated with disease
activity.59,62
Further evidence for an involvement of vitamin D
metabolism in the pathogenesis of RA is based on the fol-
lowing observations, suggesting a local action for vitamin D
metabolites in the modulation of joint inﬂammation:
1,25(OH)2D and 25(OH)D are detectable in synovial ﬂuid63;
VDR is expressed in the synovial membrane of RA patients64;
VDR-knock-out mice develop a more  aggressive form of TNF-
induced arthritis with respect to mice with a normal vitamin
D function65;
TNF-blockade requires the presence of 1,25(OH)2D to
suppress Th17 activity and, consequently, synovial inﬂam-
mation in joint tissues cultures.66
The importance of understanding the role of vitamin D in
autoimmune diseases is enforced by the very high prevalence
of hypovitaminosis D in this particular setting.61,67
Relative  hypovitaminosis  D  and  secondary
hyperparathyroidism  in  autoimmune  rheumatic  diseases
An impairment of Vitamin D system has already been postu-
lated as a concausal factor in the pathogenesis of osteoporosis
in inﬂammatory arthritis. In fact, a VDR polymorphism has
been linked to bone loss in RA; in particular68 Rass and col-
leagues found a lower BMD  in RA patients carrying the BB and
Bb genotypes of the VDR BsmI polymorphism with respect to
carriers of the bb genotype. These results suggest that the B
allele may be a marker for increased bone reabsorption and
bone loss in RA. In addition, we recently described a signif-
icantly higher PTH concentration in 105 patients affected by
autoimmune rheumatic diseases with respect to 1020 controls
despite similar plasma vitamin D concentration. These ﬁnd-
ings held true also categorizing patients in different groups
according to different vitamin D thresholds. We  also observed
that patients showed a higher prevalence of hyperparathy-
roidism than controls. Finally, at stepwise logistic regression
analysis, plasma 25(OH)D <75 nmoL/L, age ≥65 years and the
presence of an autoimmune rheumatic disease were indepen-
dent predictors for hyperparathyroidism.2
This result has been conﬁrmed in a further paper,
in which we  observed that suppression of secondary 0 1 5;5 5(3):256–263
hyperparathyroidism in autoimmune rheumatic patients was
impaired with respect to patients affected by osteoarthritis
after a cholecalciferol regimen used to correct hypovita-
minosis D.69
Similarly, in a multicentric study, RA patients with ero-
sive evolution presented with higher PTH and lower BMD in
comparison to patients with less aggressive arthritis, despite
possessing similar vitamin D concentrations.70
These observations raise the attention on the possible pres-
ence of a “relative hypovitaminosis D” in RA and in other
inﬂammatory rheumatic diseases, which could explain the
reduction in the physiological actions of this molecule; in
these patients, indeed, the mechanisms that regulate PTH
synthesis seem to be more refractory to vitamin D suppres-
sion.
A possible explanation for these ﬁndings is that chronic
inﬂammation may reduce parathyroid cells sensitivity to
1,25(OH)2D; the reduced sensitivity of parathyroid cells
could reﬂect a more  complex refractoriness to 1,25(OH)2D
actions, involving immune cells too. Alternatively, since
the active vitamin D metabolite has immunosuppressive
and immunoregulatory effects, during chronic inﬂammation,
immune cells may consume higher quantities of 1-25(OH)2D,
lowering its availability to parathyroid cells with consequent
PTH hyperproduction.
So in this setting, the vitamin D/PTH system seems to be
somehow altered and this dysfunction could participate sig-
niﬁcantly in the pathogenesis of osteoporosis in rheumatic
patients, and may represent a promising therapeutic target.
At the best of our knowledge, very few studies evaluated the
best supplementation regimen of cholecalciferol in rheumatic
patients. We  have demonstrated that only a high dose supple-
mentation regimen (300,000 IU orally once) followed by a
maintenance dose was superior, also if still suboptimal, in
the correction of hypovitaminosis D and of secondary hyper-
parathyroidism in rheumatic patients.70
Conclusions
In the last few years the same deﬁnition of “vitamin D” has
been debated and remains the subject of intense controversy.
In fact, vitamin D is not only obtained by dietary intake, like the
other vitamins, since its greater amount derives from endoge-
nous synthesis. Importantly, the concept of “vitamin” is static,
while vitamin D and PTH participate in dynamic system act-
ing on several biological targets. For these reasons vitamin D
is currently, more  correctly, deﬁned as “hormone D”; in fact
the relationship between vitamin D and PTH shares many
similarities with the other endocrine networks.
Obtaining a normal vitamin D status is paramount in
preventing RA related osteoporosis and the correction of
a deﬁcient vitamin D status should be suggested to each
rheumatic patient. However, since the correlation between
vitamin D and PTH is less linear in RA, this system is not
correctly deﬁned by the single evaluation of plasma 25(OH)D
concentration. Many patients with a normal vitamin D con-
centration are affected by secondary hyperparathyroidism
and present an inadequate vitamin D status. Therefore, we
propose that in rheumatic diseases both Vitamin D and PTH





























3r e v b r a s r e u m a t o l
re measured to establish the need for cholecalciferol supple-
entation, and that Vitamin D supplementation is targeted
o the correction of hyperparathyroidism rather than to the
ormalization of plasma 25(OH)D concentration alone.
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